Brexanolone: First Global Approval

  title={Brexanolone: First Global Approval},
  author={Lesley J. Scott},
  • L. Scott
  • Published 1 May 2019
  • Biology, Medicine
  • Drugs
Brexanolone (ZULRESSO™) is an intravenously administered, small molecule, neuroactive steroid GABAA receptor positive allosteric modulator that was developed by Sage Therapeutics under license to the University of California for the treatment of postpartum depression (PPD). The formulation is a mixture of allopregnanolone, an endogenous inhibitory pregnane neurosteroid, and sulfobutylether-beta-cyclodextrin (a solubilizing agent). In mid-March 2019 brexanolone received its first global approval… 

Allopregnanolone-based treatments for postpartum depression: Why/how do they work?

The role of allopregnanolone in depressive-like behaviors: Focus on neurotrophic proteins

Neuroactive Type-A γ-Aminobutyric Acid Receptor Allosteric Modulator Steroids from the Hypobranchial Gland of Marine Mollusk, Conus geographus.

Five steroids, conosteroids A-E (1-5), from the hypobranchial gland of the mollusk Conus geographus are isolated, expanding the known chemical space of neuroactive steroids.

Neurosteroids and Affective Disorders in Women

The relation of neurosteroids with affective disorders in women and novel treatments in this regard are described in an understandable and synthesized review of the subject.

2-(Fluoromethoxy)-4'-(S-methanesulfonimidoyl)-1,1'-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson's Disease.

Tolerance development caused by dopamine replacement with l-DOPA and therapeutic drawbacks upon activation of dopaminergic receptors with orthosteric agonists reveal a significant unmet need for safe

New drug approvals for 2019: Synthesis and clinical applications.

Prenatal exposure to bisphenols and phthalates and postpartum depression: The role of neurosteroid hormone disruption.

Endocrine disrupting chemicals may influence hormonal shifts during pregnancy as well as contribute to PPD.

The Role of HPA Axis and Allopregnanolone on the Neurobiology of Major Depressive Disorders and PTSD

The neurophysiological role of allopregnanolone both as a potent and positive GABAergic neuromodulator but also in its capacity of inhibiting the HPA axis is reviewed.



Open‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression

Brexanolone (USAN; formerly SAGE‐547 Injection), a proprietary injectable allopregnanolone formulation, was evaluated as a treatment for severe PPD in a proof‐of‐concept, open‐label study.

Brexanolone: an allosteric modulator of GABA-A receptors in the rapid treatment of postpartum depression

Findings lend support to the hypothesis that changes in neuroactive steroid concentrations during pregnancy and postpartum are capable of provoking affective dysregulation in mothers and reflect the relative involvement of various functional neuroanatomical systems.

Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development

A recent series of open-label and placebo-controlled randomized clinical trials of brexanolone in postpartum depression demonstrated a rapid reduction in depressive symptoms, and has led to the submission for regulatory approval to the US Food and Drug Administration.

Allopregnanolone as a mediator of affective switching in reproductive mood disorders

The role of the “neuroactive” steroids estradiol and progesterone in reproductive endocrine-related mood disorders are described and potential mechanisms by which ALLO might contribute to their pathophysiology are highlighted.

The role of reproductive hormones in postpartum depression

The hypothesis that fluctuations in reproductive hormone levels during pregnancy and the postpartum period trigger PPD in susceptible women is examined to propose that these women constitute a “hormone-sensitive” PPD phenotype, which should be studied independent of other PPD phenotypes to identify underlying pathophysiology and develop novel treatment targets.